Uncovering Transcriptomics: The Next Frontier in Blastocyst Assessment

Dr. Pere Mir Pardo, PGT Development manager, Vitrolife Group, Spain and Dr. Carmen Rubio, VP R&D Genetic Services, Vitrolife Group

Since its inception, PGT-A has proven to be an effective tool for embryo evaluation and selection, but in recent years, the ability to provide incremental improvements has proven more difficult. Have we reached the ceiling with information we can glean from DNA analysis?
As a pioneer and leader in reproductive genetics, we’re taking the next step in preimplantation genetic testing to unlock information beyond aneuploidies using both DNA and RNA with the most advanced amplification and leading-edge sequencing technology. We’ve come a long way, but we still have so much to uncover. Come with us as we journey to the dark side of…the embryo.

This presentation was part of Vitrolife Group live Academy Studios from ESHRE 2026.